Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text

Medicine, Cell Biology, Bone Metabolism +13

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martín, Michael R. McClung et al. · New England Journal of Medicine · 2009 · 3.4K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

George H. Nancollas, Ruikang Tang, Roger Phipps et al. · Bone · 2005 · 859 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +12

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 611 citations

Medicine, Endocrinology, Bone Metabolism +16

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, Richard L. Prince, Chad Deal et al. · Journal of Bone and Mineral Research · 2008 · 604 citations

Medicine, Pharmacotherapy, Bone Metabolism +16